Orna Therapeutics to Acquire ReNAgade Therapeutics
- 5.23.2024
On May 23, Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months. The partnership will combine Orna and ReNAgade’s technological capabilities to drive R&D that is uniquely focused on circular RNA therapeutics.
The WilmerHale team advising Orna Therapeutics was led by Rosemary Reilly and Mark Nylen, and included Rebecca Nauta, Joe Odegaard, Nick Andreacchi, Bill Caporizzo, Meghan Walsh, Amy Null, Jenna Ventorino and Senior Paralegal Cindy Sullivan.
